Abivax receives a "Strong Buy" rating, driven by positive phase 3 ABTECT induction data for obefazimod in moderate-to-severe ...

African Swine Fever Virus, ASFV, Viral Entry, Host Cell Invasion, CD163, Siglec-1, Macropinocytosis, Endosomal Escape, Immune Evasion, Signaling Pathways Share and Cite: Marcelino, K.B. and Fang, G.J.

Syndax Pharmaceuticals, Inc. ( SNDX) The 67th American Society of Hematology ( ASH) Annual Meeting December 8, 2025 7:00 AM EST ...

Onctura initiates phase I/II trial of roginolisib in patients with myelofibrosis who are no longer responding to JAK inhibition: Geneva, Switzerland Friday, December 5, 2025, 15: ...

Onctura, a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers, today announces it has dosed the first patient in its Phase I/II clinical trial evaluating ...

What have we learned from all randomized controlled trials with new agents added on to standard of care for the treatment of patients with systemic lupus erythematosus (SLE)? While positive studies ...

Panelists discuss how the expanding treatment landscape for Crohn’s disease includes multiple mechanisms of action such as anti-tumor necrosis factor (TNF) agents, anti-integrin agents, interleukin ...

Please provide your email address to receive an email when new articles are posted on . In a Healio video exclusive, Edward V. Loftus Jr., MD, discusses the potential of tumor necrosis factor-like ...

The time to onset of action for the treatment of plaque psoriasis was fastest with the interleukin-17 inhibitor bimekizumab, with an estimated effect time of 5.9 weeks. Interleukin (IL)-17 inhibitors, ...

VGT-1849B, a selective JAK2 inhibitor, targets JAK2 mRNA to reduce protein production, potentially improving safety profiles over existing therapies. Polycythemia vera is a rare myeloproliferative ...

Real-world data suggested similar effectiveness with tofacitinib or ustekinumab for ulcerative colitis patients with prior biologic failures. However, among those exposed to three or more advanced ...

WAYNE, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for ...